David V Serreze
Overview
Explore the profile of David V Serreze including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
2281
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skelly D, Graham J, Cheng M, Furuta M, Walter A, Stoklasek T, et al.
bioRxiv
. 2024 Jul;
PMID: 39071392
Identifying host genetic factors modulating immune checkpoint inhibitor (ICI) efficacy has been experimentally challenging because of variations in both host and tumor genomes, differences in the microbiome, and patient life...
2.
Serreze D, Dwyer J, Racine J
Cold Spring Harb Perspect Med
. 2024 Jun;
14(10).
PMID: 38886067
Multiple rodent models have been developed to study the basis of type 1 diabetes (T1D). However, nonobese diabetic (NOD) mice and derivative strains still provide the gold standard for dissecting...
3.
Racine J, Bachman J, Zhang J, Misherghi A, Khadour R, Kaisar S, et al.
J Immunol
. 2024 Mar;
212(8):1287-1306.
PMID: 38426910
Myocarditis has emerged as an immune-related adverse event of immune checkpoint inhibitor (ICI) cancer therapy associated with significant mortality. To ensure patients continue to safely benefit from life-saving cancer therapy,...
4.
Ye C, Clements S, Gu W, Geurts A, Mathews C, Serreze D, et al.
Proc Natl Acad Sci U S A
. 2023 Nov;
120(49):e2312039120.
PMID: 38015847
In both humans and NOD mice, type 1 diabetes (T1D) develops from the autoimmune destruction of pancreatic beta cells by T cells. Interactions between both helper CD4 and cytotoxic CD8...
5.
Racine J, Misherghi A, Dwyer J, Maser R, Forte E, Bedard O, et al.
J Immunol
. 2023 Oct;
211(12):1792-1805.
PMID: 37877672
In an effort to improve HLA-"humanized" mouse models for type 1 diabetes (T1D) therapy development, we previously generated directly in the NOD strain CRISPR/Cas9-mediated deletions of various combinations of murine...
6.
Ciecko A, Wang Y, Harleston S, Drewek A, Serreze D, Geurts A, et al.
J Immunol
. 2023 Feb;
210(7):935-946.
PMID: 36762954
IL-21 is essential for type 1 diabetes (T1D) development in the NOD mouse model. IL-21-expressing CD4 T cells are present in pancreatic islets where they contribute to T1D progression. However,...
7.
Racine J, Morel L, Chen Y, Serreze D
Front Immunol
. 2022 Nov;
13:1069232.
PMID: 36389740
No abstract available.
8.
Dwyer J, Racine J, Chapman H, Quinlan A, Presa M, Stafford G, et al.
J Immunol
. 2022 Jun;
209(2):227-237.
PMID: 35760520
Type 1 diabetes (T1D) in both humans and NOD mice is caused by T cell-mediated autoimmune destruction of pancreatic β cells. Increased frequency or activity of autoreactive T cells and...
9.
Break T, Oikonomou V, Dutzan N, Desai J, Swidergall M, Freiwald T, et al.
Science
. 2021 Sep;
373(6561):eabi8835.
PMID: 34529475
Puel and Casanova and Kisand . challenge our conclusions that interferonopathy and not IL-17/IL-22 autoantibodies promote candidiasis in autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy. We acknowledge that conclusive evidence for causation is difficult...
10.
Ciecko A, Foda B, Barr J, Ramanathan S, Atkinson M, Serreze D, et al.
Cell Rep
. 2021 Feb;
34(5):108725.
PMID: 33535031
No abstract available.